文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

瑞典锂盐与丙戊酸盐使用相关的肾脏结局绝对与相对风险

Absolute and Relative Risks of Kidney Outcomes Associated With Lithium vs Valproate Use in Sweden.
PubMed 文献 · JAMA Netw Open · 2023-07-03
一句话结论新使用锂盐者10年CKD绝对风险低(8.4%)且与丙戊酸盐(8.2%)无差异,但血锂>1.0 mmol/L与CKD进展及AKI风险升高相关,强调密切监测与剂量调整。

该队列研究纳入瑞典斯德哥尔摩2007年1月1日至2018年12月31日新使用锂盐(5308例)或丙戊酸盐(5638例)的10946例患者,中位随访4.5年。锂盐组与丙戊酸盐组相比,CKD进展(HR 1.11,95%CI 0.86-1.45)和AKI(HR 0.88,95%CI 0.70-1.10)风险无显著差异,10年CKD绝对风险分别为8.4%和8.2%。超过35000次常规血锂检测中仅3%处于中毒范围(>1.0 mmol/L);血锂>1.0 mmol/L与≤1.0 mmol/L相比,CKD进展(HR 2.86,95%CI 0.97-8.45)和AKI(HR 3.51,95%CI 1.41-8.76)风险升高。作者认为血锂升高与未来肾脏风险相关,尤其AKI,需密切监测并调整锂盐剂量。

要点

  • 新使用锂盐与丙戊酸盐相比,CKD进展(HR 1.11,95%CI 0.86-1.45)和AKI(HR 0.88,95%CI 0.70-1.10)风险无显著差异。
  • 10年CKD绝对风险低且两组相似:锂盐组8.4%,丙戊酸盐组8.2%。
  • 超过35000次常规血锂检测中仅3%结果处于中毒范围(>1.0 mmol/L)。
  • 血锂>1.0 mmol/L与≤1.0 mmol/L相比,CKD进展HR 2.86(95%CI 0.97-8.45),AKI HR 3.51(95%CI 1.41-8.76)。
  • 作者强调血锂升高与未来肾脏风险相关,尤其AKI,需密切监测和锂盐剂量调整。

适用人群与场景

  • 2007年1月1日至2018年12月31日新开始锂盐或丙戊酸盐治疗的双相障碍患者,中位随访4.5年(IQR 1.9-8.0年)。
  • 数据来自瑞典斯德哥尔摩所有成年居民的常规医疗数据(Stockholm Creatinine Measurements项目)。

诊断标准与关键阈值

  • CKD进展定义为估算肾小球滤过率(eGFR)较基线下降>30%和肾衰竭的复合终点。
  • AKI定义为诊断或一过性肌酐升高。
  • 血锂中毒范围定义为>1.0 mmol/L。

研究设计与关键结果

  • 研究类型:新使用者活性对照队列研究,使用逆概率治疗加权减少混杂;纳入10946例(中位年龄45岁,IQR 32-59;女性6227例,56.9%),其中锂盐组5308例、丙戊酸盐组5638例。
  • 随访期间共发生421例CKD进展事件和770例AKI事件。
  • 与丙戊酸盐组相比,锂盐组CKD进展风险无显著升高(HR 1.11,95%CI 0.86-1.45),AKI风险无显著差异(HR 0.88,95%CI 0.70-1.10)。
  • 10年CKD绝对风险:锂盐组8.4%,丙戊酸盐组8.2%。
  • 两组新发白蛋白尿风险及eGFR年下降速率无差异。
  • 超过35000次常规血锂检测中,仅3%结果>1.0 mmol/L。
  • 血锂>1.0 mmol/L与≤1.0 mmol/L相比,CKD进展HR 2.86(95%CI 0.97-8.45),AKI HR 3.51(95%CI 1.41-8.76)。

证据类型、等级与局限

  • 证据类型:队列研究(新使用者活性对照设计,逆概率治疗加权)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为血锂升高与未来肾脏风险相关,尤其AKI,强调需要密切监测和锂盐剂量调整。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Among patients with bipolar disorder, discordant findings have been published on the nephrotoxic effects of lithium therapy.

OBJECTIVE: To quantify absolute and relative risks of chronic kidney disease (CKD) progression and acute kidney injury (AKI) in people who initiated lithium compared with valproate therapy and to investigate the association between cumulative use and elevated lithium levels and kidney outcomes.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study had a new-user active-comparator design and used inverse probability of treatment weights to minimize confounding. Included patients initiated therapy with lithium or valproate from January 1, 2007, to December 31, 2018, and had a median follow-up of 4.5 years (IQR, 1.9-8.0 years). Data analysis began in September 2021, using routine health care data from the period 2006 to 2019 from the Stockholm Creatinine Measurements project, a recurrent health care use cohort of all adult residents in Stockholm, Sweden.

EXPOSURES: New use of lithium vs new use of valproate and high (>1.0 mmol/L) vs low serum lithium levels.

MAIN OUTCOMES AND MEASURES: Progression of CKD (composite of >30% decrease relative to baseline estimated glomerular filtration rate [eGFR] and kidney failure), AKI (by diagnosis or transient creatinine elevations), new albuminuria, and annual eGFR decrease. Outcomes by attained lithium levels were also compared in lithium users.

RESULTS: The study included 10 946 people (median [IQR] age, 45 [32-59] years; 6227 female [56.9%]), of whom 5308 initiated lithium therapy and 5638 valproate therapy. During follow-up, 421 CKD progression events and 770 AKI events were identified. Compared with patients who received valproate, those who received lithium did not have increased risk of CKD (hazard ratio [HR], 1.11 [95% CI, 0.86-1.45]) or AKI (HR, 0.88 [95% CI, 0.70-1.10]). Absolute 10-year CKD risks were low and similar: 8.4% in the lithium group and 8.2% in the valproate group. No difference in the risk of developing albuminuria or the annual rate of eGFR decrease was found between groups. Among more than 35 000 routine lithium tests, only 3% of results were in the toxic range (>1.0 mmol/L). Lithium values greater than 1.0 mmol/L, compared with lithium values of 1.0 mmol/L or less, were associated with increased risk of CKD progression (HR, 2.86; 95% CI, 0.97-8.45) and AKI (HR, 3.51; 95% CI, 1.41-8.76).

CONCLUSIONS AND RELEVANCE: In this cohort study, compared with new use of valproate, new use of lithium was meaningfully associated with adverse kidney outcomes, with low absolute risks that did not differ between therapies. However, elevated serum lithium levels were associated with future kidney risks, particularly AKI, emphasizing the need for close monitoring and lithium dose adjustment.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Bosi A, Clase CM, Ceriani L, et al. Absolute and Relative Risks of Kidney Outcomes Associated With Lithium vs Valproate Use in Sweden. JAMA Netw Open. 2023. PMID: 37418264. doi:10.1001/jamanetworkopen.2023.22056

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。